Maximus (NYSE:MMS) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut shares of Maximus (NYSE:MMS) from a buy rating to a hold rating in a report released on Saturday morning.

A number of other equities analysts also recently commented on the company. Weiss Ratings restated a “buy (b-)” rating on shares of Maximus in a report on Monday, December 29th. Zacks Research raised shares of Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

Maximus Price Performance

Maximus stock opened at $75.17 on Friday. Maximus has a 1 year low of $63.77 and a 1 year high of $100.00. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.64 and a current ratio of 2.34. The firm has a 50 day moving average price of $90.07 and a 200 day moving average price of $86.48. The company has a market cap of $4.10 billion, a price-to-earnings ratio of 11.44 and a beta of 0.57.

Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.01. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. Maximus’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter last year, the business earned $1.61 EPS. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. Sell-side analysts predict that Maximus will post 6.15 earnings per share for the current year.

Maximus Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a dividend of $0.33 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Maximus’s previous quarterly dividend of $0.30. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.8%. Maximus’s dividend payout ratio is presently 18.26%.

Insider Buying and Selling at Maximus

In related news, insider Michelle F. Link sold 4,039 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total transaction of $350,746.76. Following the completion of the sale, the insider directly owned 19,542 shares of the company’s stock, valued at approximately $1,697,027.28. This trade represents a 17.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.80% of the company’s stock.

Institutional Trading of Maximus

Several large investors have recently modified their holdings of the business. Farther Finance Advisors LLC boosted its holdings in Maximus by 69.0% in the fourth quarter. Farther Finance Advisors LLC now owns 284 shares of the health services provider’s stock valued at $25,000 after purchasing an additional 116 shares during the last quarter. Richardson Financial Services Inc. increased its holdings in Maximus by 123.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 348 shares of the health services provider’s stock worth $32,000 after purchasing an additional 192 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Maximus in the 3rd quarter valued at approximately $32,000. Canada Pension Plan Investment Board purchased a new position in shares of Maximus during the 2nd quarter valued at approximately $35,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in shares of Maximus during the third quarter worth approximately $38,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Maximus

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Q1 EPS narrowly beat expectations — Maximus reported $1.85 EPS vs. the $1.84 consensus, showing earnings strength and year‑over‑year EPS improvement. Maximus (MMS) Q1 Earnings Top Estimates
• Positive Sentiment: Margins improved — management emphasized margin gains and cost discipline during the call, which supports near‑term profitability despite revenue pressure. Maximus Earnings Call: Margins Rise Amid Revenue Pressure
• Neutral Sentiment: Full disclosure and investor materials posted — the company released the press release, slide deck and earnings‑call transcript for detailed review (useful for modeling/QA but not market moving by itself). View Press Release / Slide Deck
• Negative Sentiment: Revenue miss and YoY decline — Q1 revenue was $1.35B vs. ~$1.37B expected and fell ~4.1% year‑over‑year, signaling near‑term top‑line weakness. Maximus Q1 results and materials
• Negative Sentiment: Tightened / lower FY‑2026 revenue guidance — management set FY‑2026 revenue of $5.2B–$5.4B (below Street ~ $5.5B) and EPS guidance of $8.05–$8.35 (around but slightly below consensus midpoint), which pressured growth expectations. Maximus tops Q1 earnings forecasts while tightening 2026 revenue guidance

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.